菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

In Vivo Pharmacology Services

Drug Development Expertise Empowering Research Services for Biologics

Science-Driven Solutions via Multi-Species Platforms


Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies and immunohistochemical staining. With a proven track record of over 800 projects, we support a wide variety of therapeutic modalities, such as monoclonal, bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and CAR-T therapies. Our comprehensive platform covers diverse therapeutic areas such as oncology, autoimmune diseases, and metabolic disorders, ensuring a seamless transition from preclinical research to clinical trials, IND filings, and beyond.

 

Key Features of Our In Vivo Pharmacology Services:

  • Pharmacokinetics and Pharmacodynamics (PKPD), Anti-Drug Antibody (ADA) & Exploratory Toxicity: Assess drug behavior, immune response, and preliminary safety profiles
  • Efficacy Studies: Conduct across a range of disease and tumor models
  • In Vivo Imaging & Biodistribution: Real-time tracking of therapeutic antibody candidates within living organisms
  • Immunohistochemistry (IHC): Perform precise tissue analysis and detect biomarkers
  • Mechanism of Action (MOA) Studies: Elucidate drug efficacy, mechanisms, and pathways

 

PKPD and Toxicity Studies

One-stop PK/PD/Tox studies for dose-concentration-response and safety dosage optimization

 

 

Our PKPD and toxicology studies provide multi-species evaluations to assess dose-concentration-response relationships and establish safe dosage levels while minimizing drug-related toxicity. We deliver customized solutions tailored to diverse in vivo pharmacology needs.

 

Key Features: 

 

  • Comprehensive PK/PD/Tox evaluation using NHP, murine, canine, and swine models
  • Extensive NHP platforms for early discovery with monkeys scheduled within 7 days
  • Customized assays tailored for mAbs, bsAbs, ADCs & novel modalities
  • Cost-effective hFcRn mouse model for Fc engineering assessment

 

Case Study

 

 

Efficacy Studies

Validated in vivo efficacy models for oncology, autoimmune, and metabolic diseases

 

 

Our in vivo efficacy services focus on lead screening and dosage optimization using oncology models, such as syngeneic and CDX/PBMC models. For autoimmune and metabolic diseases, we offer over 30 validated models representing diverse clinical symptoms for customized preclinical studies.

 

Key Features: 
 
  • Diverse disease models: Oncology (syngeneic, CDX/PBMC, IVIS), and autoimmune & metabolic diseases
  • Rational design to align preclinical models with human disease biology
  • Tailored solutions for troubleshooting and data interpretation

 

Case Study

Immunohistology

Precise immunohistochemistry (IHC) and immunofluorescence (IF) studies

 

 

Our immunohistology services offer microscopic analysis and tissue diagnostics to support drug development, including target validation, drug-related toxicity assessment, and mechanism of action (MOA) studies for various antibody leads.

 

Key Features: 
 
  • Robust IHC and IF services utilizing advanced multi-staining techniques
  • Microscopic analysis and tissue diagnostics for target validation, drug-related toxicity, and MOA studies
  • Reliable, high-quality analysis with expert data interpretation

 

Case Study

Discuss Your In Vivo Pharmacology Project
with Our Experts

Contact Us

PKPD and Toxicology Case Study

 

 

This case study provides a comprehensive in vivo PK/PD/Tox evaluation of a bispecific T-cell engager (TCE). PK studies included pharmacokinetic profiling and tissue biodistribution. PD studies involved immunophenotyping and receptor occupancy assessments. Toxicology studies incorporated cytokine monitoring, hematology tracking, and immunohistochemical staining.

 

 

Efficacy Case Study

 

 

We selected a rational tumor model using IHC target validation and routine donor screening to ensure reliable efficacy and a consistent therapeutic window. This selected CDX/PBMC model demonstrated high resolution and superior efficacy in tumor volume measurements treated by bispecific T-cell engagers (TCEs).

 

 

Immunohistology Case Study

 

 

This case study demonstrates the use of IHC and IF staining techniques for tumor model characterization, drug distribution analysis, and immune profiling. Tumor antigen IHC guided model selection, Fc IHC confirmed ADC distribution, CD4 IHC identified T cell infiltration, and multiplex IF provided comprehensive immune profiling.

 

 

 

Your Project. Our Expertise.

Contact Us

Posters & Flyers

Webinars

 

In Vivo Pharmacology Maximizing Translational Relevance via NHP/Murine Models

 

In this webinar, you will gain valuable insights into: 

 

  • Rational study design to align preclinical models with human disease biology
  • Key considerations for selecting optimal species and models that maximize translational relevance of PK/PD and efficacy
  • Data interpretation to extract actionable insights from complex pharmacodynamic and histological datasets
  • Proactive troubleshooting to overcome preclinical challenges and accelerate timelines

 

 

Watch the Webinar On-Demand Now

 

Early-Stage Developability Assessment for Lead Optimization

 

In this webinar, you will gain valuable insights into: 

 

  • High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability
  • Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage
  • Micro-developability strategy for new modalities

 

 

Watch the Webinar On-Demand Now

In Vivo Pharmacology Services:
Science-Driven Solutions via Multi-Species Platforms

 

Our end-to-end, multi-species in vivo pharmacology services offer science-driven solutions for preclinical studies, including PKPD evaluations, efficacy models, toxicology and immunohistochemical studies. With a proven track record of over 800 successful projects, we support a wide range of therapeutic modalities, such as monoclonal, bispecific, and multispecific antibodies, ADCs, fusion proteins, and CAR-T therapies. Our comprehensive platform covers key therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders, supporting a seamless transition from preclinical research to clinical trials, IND filings, and beyond.

Stay On The Forefront Of Biologics
Discovery & Development

Follow us on LinkedIn